In the last trading session, 2.16 million iBio Inc (AMEX:IBIO) shares changed hands as the company’s beta touched 1.44. With the company’s per share price at $3.89 changed hands at $0.45 or 13.08% during last session, the market valuation stood at $38.41M. IBIO’s last price was a discount, traded about -28.02% off its 52-week high of $4.98. The share price had its 52-week low at $1.05, which suggests the last value was 73.01% up since then.
Analysts gave the iBio Inc (IBIO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended IBIO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. iBio Inc’s EPS for the current quarter is expected to be -0.32.
iBio Inc (AMEX:IBIO) trade information
Instantly IBIO was in green as seen at the end of in last trading. With action 5.71%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 58.78%, with the 5-day performance at 5.71% in the green. However, in the 30-day time frame, iBio Inc (AMEX:IBIO) is 26.71% up.
The consensus price target for the stock as assigned by Wall Street analysts is 3.6, meaning bulls need a downside of -8.06% from its current market value. According to analyst projections, IBIO’s forecast low is 3.6 with 3.6 as the target high. To hit the forecast high, the stock’s price needs a 7.46% surge from its current level, while the stock would need to tank 7.46% for it to hit the projected low.
iBio Inc (IBIO) estimates and forecasts
Year-over-year growth is forecast to reach 77.78% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 100k. 2 analysts are of the opinion that iBio Inc’s revenue for the current quarter will be 100k. The estimates for the next quarter sales put growth at -42.86%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 57.55%. The 2025 estimates are for iBio Inc earnings to increase by 60.55%, but the outlook for the next 5-year period is at 45.01% per year.
IBIO Dividends
iBio Inc is expected to release its next quarterly earnings report in March.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund . With 46.78 shares estimated at $0.18 million under it, the former controlled 0.47% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.36% of the shares, roughly 36.0 shares worth around $0.14 million.
